In addition to the normal aspects of organizing clinical trials, the launch of a chemoprevention trial on prostate cancer needs extra effort. The sample size and duration of follow-up is so extensive that such a trial should be organized as an intergroup study, preferably worldwide. For that a central data center and data management is mandatory. Because healthy individuals are involved, refusal, loss to follow-up and inadequate adherence may be substantial. The choice of the study endpoint presence of prostate cancer or death due to prostate cancer will lead to completely different sample sizes and length of follow-up. Of criteria leading to the diagnosis of prostate cancer (PSA, DRE and transrectal ultrasound), at least two are rather subjective. The drug involved might affect the criteria for diagnosis. Because of the high incidence of clinically nonsignificant prostate cancer of men over 55, a large number of nonrelevant prostate cancers will be detected in both arms. Due to the long follow-up and alterations in the state of the art of detection and therapy of prostate cancer, the completion of such a study might be hampered. If the average price per patient involved in a clinical trial is currently between USD 1,000 and 2,000, one may calculate that for 30,000 men, USD 20–40 million are needed, not including the hospital visits, examinations and biopsies. Economic considerations thus play a major role in organizing trials on the chemoprevention of prostate cancer.

Keywords:
Chemoprevention, Prostate cancer, Practical aspects
1.
Lippman SM, Benner SE, Waun KH: Cancer chemoprevention. J Clin Oncol 1994;12:851–873.
2.
Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953;6:963–968.
3.
Bertram JS, Kolonel LN, Meyskens FL: Rationale and strategies for chemoprevention of cancer in humans Cancer Res 1987;47:3012–3031.
4.
Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR: Familial patterns of prostate cancer: A case-control analysis. J Urol 1991;146:1305.
5.
Lippman SM, Lee JS, Lotan R et al: Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990;82:555–560.
6.
Boone CW, Kelloff GJ, Steele VE: Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 1991;52:1651–1659.
7.
Feigl P, Blumenstein B, Thompson I et al: Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995;16:150–163.
8.
Goodman GE: The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II and III objectives. Cancer Res 1992;52(suppl):2752–2757.
9.
Vogelstein B, Fearon ER, Hamilton SR: Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525–532.
10.
Slovic P: Perception of risk. Science 1987;236:280–285.
11.
Freedman LS: The effect of partial noncompliance on the power of the clinical trial. Control Clin Trials 1990;11:157–168.
12.
Gann PH, Manson JE, Glynn RJ: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220–1224.
13.
Buring JE, Hennekens CH: The Women’s Health Study: Summary of the study design. J Myocard Ischemia 1992;4:27–29.
14.
Holund B: Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980;14:29–35.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.